Related Experiment Video
Updated: Jan 31, 2026
Dual-mode Imaging of Cutaneous Tissue Oxygenation and Vascular Function
Published on: December 8, 2010
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
William Damsky1, Durga Thakral1, Nkiruka Emeagwali1
1From the Departments of Dermatology (W.D., D.T., A.G., B.K.), Immunobiology (W.D.), and Pathology (A.G.) and the Department of Internal Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine (N.E.), Yale School of Medicine, New Haven, CT.
Abstract:
There is evidence that Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling plays a role in the pathogenesis of sarcoidosis. We treated a patient with cutaneous sarcoidosis with the JAK inhibitor tofacitinib; the patient had not previously had a response to medications and had not received systemic glucocorticoids. This treatment resulted in clinical and histologic remission of her skin disease. Sequencing of RNA and immunohistochemical examination of skin-lesion samples obtained from the patient before and during therapy and immunohistochemical testing of lesion samples obtained from other patients with cutaneous sarcoidosis support a role for JAK-STAT signaling in cutaneous sarcoidosis. (Funded by the Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research and others.).
Insights
Tofacitinib, a Janus kinase (JAK) inhibitor, effectively treated a patient with severe cutaneous sarcoidosis. This JAK-STAT pathway targeted therapy led to complete remission, suggesting its therapeutic potential for this condition.
Area of Science:
- Immunology
- Dermatology
- Molecular Biology
Background:
- The pathogenesis of sarcoidosis involves the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway.
- Cutaneous sarcoidosis is a challenging condition often resistant to conventional therapies.
Observation:
- A patient with refractory cutaneous sarcoidosis was treated with tofacitinib, a JAK inhibitor.
- The patient had not responded to previous treatments, including systemic glucocorticoids.
Findings:
- Tofacitinib treatment resulted in both clinical and histologic remission of the patient's skin lesions.
- RNA sequencing and immunohistochemical analyses of skin biopsies supported the role of JAK-STAT signaling in cutaneous sarcoidosis pathogenesis.
- These molecular findings were further corroborated by examining samples from other patients with the condition.
Implications:
- Targeting the JAK-STAT pathway with inhibitors like tofacitinib represents a promising therapeutic strategy for cutaneous sarcoidosis.
- This study provides evidence for the clinical utility of JAK inhibitors in managing difficult-to-treat sarcoidosis.
- Further research into JAK-STAT signaling in sarcoidosis may uncover additional therapeutic targets.
Related Concept Videos
02:00Molecular Models
03:51Molecular Orbital Theory II
02:35Molecular Orbital Theory I
02:27Predicting Molecular Geometry
02:54Molecular and Ionic Solids
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
03:07Kinetic Molecular Theory: Molecular Velocities, Temperature, and Kinetic Energy